ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Clomid for PCT, fertility or low T
Failed PCT - Getting Off TRT for Fertility Purposes
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="ajax31" data-source="post: 175018" data-attributes="member: 39208"><p>This won't make me popular around here, but, if I were you, I would consider adding a low-dose AI to your proposed clomiphene trial.</p><p></p><p><a href="https://www.ncbi.nlm.nih.gov/pubmed/32202084#" target="_blank">World J Mens Health.</a> 2020 Feb 24. doi: 10.5534/wjmh.190160. [Epub ahead of print]</p><p><span style="font-size: 26px"><strong>Obesity and Baseline Estradiol Levels Are Independent Predictors for Initiation of Anastrozole in Hypogonadal Men on Clomiphene Citrate.</strong></span></p><p><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Keihani%20S%5BAuthor%5D&cauthor=true&cauthor_uid=32202084" target="_blank">Keihani S</a>1, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Alder%20NJ%5BAuthor%5D&cauthor=true&cauthor_uid=32202084" target="_blank">Alder NJ</a>2, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Cheng%20PJ%5BAuthor%5D&cauthor=true&cauthor_uid=32202084" target="_blank">Cheng PJ</a>2, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Stoddard%20GJ%5BAuthor%5D&cauthor=true&cauthor_uid=32202084" target="_blank">Stoddard GJ</a>3, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Pastuszak%20AW%5BAuthor%5D&cauthor=true&cauthor_uid=32202084" target="_blank">Pastuszak AW</a>2, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Hotaling%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=32202084" target="_blank">Hotaling JM</a>2.</p><p><span style="font-size: 18px"><strong><a href="https://www.ncbi.nlm.nih.gov/pubmed/32202084#" target="_blank">Author information</a></strong></span></p><p><span style="font-size: 18px"><strong></strong></span></p><p><span style="font-size: 18px"><strong>Abstract</strong></span></p><p><strong>PURPOSE:</strong></p><p>To assess the conversion rate from clomiphene citrate (CC) monotherapy to combination CC+anastrozole (AZ) therapy in hypogonadal men and the predictors associated with the initiation of AZ.</p><p><strong>MATERIALS AND METHODS:</strong></p><p>A retrospective review of records from hypogonadal men treated with CC in a single fertility center was performed from 2013 to 2018. Patient age, body mass index (BMI), blood pressure, and reproductive hormones were obtained at baseline. Obesity was defined as BMI≥30 kg/m². Cox proportional hazards models were used to identify predictors of switching to combination CC+AZ therapy.</p><p><strong>RESULTS:</strong></p><p>A total of 318 men on CC were included. Median (interquartile range) age was 34 years (30-39 years) and patients were followed for a median of 9 months (4-17 months). Of these, 97 (30.5%) were started on CC+AZ therapy. These patients had higher baseline BMI and estradiol, which in multivariable regression were significant predictors for switching to CC+AZ therapy. A threshold of 18.5 pg/mL for baseline estradiol provided the highest accuracy for predicting the addition of AZ after adjusting for baseline BMI and total testosterone levels.</p><p><strong>CONCLUSIONS:</strong></p><p>In our practice, following CC monotherapy, 30% of men were initiated on CC+AZ. Obesity (BMI≥30 kg/m²) and baseline estradiol ≥18.5 pg/mL can predict the conversion to combination therapy with addition of AZ. This information can be used to counsel patients and also help to identify patients who can be started on combination therapy upfront.</p><p>Copyright © 2020 Korean Society for Sexual Medicine and Andrology.</p><p><strong>KEYWORDS:</strong></p><p>Anastrozole; Clomiphene; Hypogonadism; Infertility, male; Testosterone</p></blockquote><p></p>
[QUOTE="ajax31, post: 175018, member: 39208"] This won't make me popular around here, but, if I were you, I would consider adding a low-dose AI to your proposed clomiphene trial. [URL='https://www.ncbi.nlm.nih.gov/pubmed/32202084#']World J Mens Health.[/URL] 2020 Feb 24. doi: 10.5534/wjmh.190160. [Epub ahead of print] [SIZE=26px][B]Obesity and Baseline Estradiol Levels Are Independent Predictors for Initiation of Anastrozole in Hypogonadal Men on Clomiphene Citrate.[/B][/SIZE] [URL='https://www.ncbi.nlm.nih.gov/pubmed/?term=Keihani%20S%5BAuthor%5D&cauthor=true&cauthor_uid=32202084']Keihani S[/URL]1, [URL='https://www.ncbi.nlm.nih.gov/pubmed/?term=Alder%20NJ%5BAuthor%5D&cauthor=true&cauthor_uid=32202084']Alder NJ[/URL]2, [URL='https://www.ncbi.nlm.nih.gov/pubmed/?term=Cheng%20PJ%5BAuthor%5D&cauthor=true&cauthor_uid=32202084']Cheng PJ[/URL]2, [URL='https://www.ncbi.nlm.nih.gov/pubmed/?term=Stoddard%20GJ%5BAuthor%5D&cauthor=true&cauthor_uid=32202084']Stoddard GJ[/URL]3, [URL='https://www.ncbi.nlm.nih.gov/pubmed/?term=Pastuszak%20AW%5BAuthor%5D&cauthor=true&cauthor_uid=32202084']Pastuszak AW[/URL]2, [URL='https://www.ncbi.nlm.nih.gov/pubmed/?term=Hotaling%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=32202084']Hotaling JM[/URL]2. [SIZE=18px][B][URL='https://www.ncbi.nlm.nih.gov/pubmed/32202084#']Author information[/URL] Abstract[/B][/SIZE] [B]PURPOSE:[/B] To assess the conversion rate from clomiphene citrate (CC) monotherapy to combination CC+anastrozole (AZ) therapy in hypogonadal men and the predictors associated with the initiation of AZ. [B]MATERIALS AND METHODS:[/B] A retrospective review of records from hypogonadal men treated with CC in a single fertility center was performed from 2013 to 2018. Patient age, body mass index (BMI), blood pressure, and reproductive hormones were obtained at baseline. Obesity was defined as BMI≥30 kg/m². Cox proportional hazards models were used to identify predictors of switching to combination CC+AZ therapy. [B]RESULTS:[/B] A total of 318 men on CC were included. Median (interquartile range) age was 34 years (30-39 years) and patients were followed for a median of 9 months (4-17 months). Of these, 97 (30.5%) were started on CC+AZ therapy. These patients had higher baseline BMI and estradiol, which in multivariable regression were significant predictors for switching to CC+AZ therapy. A threshold of 18.5 pg/mL for baseline estradiol provided the highest accuracy for predicting the addition of AZ after adjusting for baseline BMI and total testosterone levels. [B]CONCLUSIONS:[/B] In our practice, following CC monotherapy, 30% of men were initiated on CC+AZ. Obesity (BMI≥30 kg/m²) and baseline estradiol ≥18.5 pg/mL can predict the conversion to combination therapy with addition of AZ. This information can be used to counsel patients and also help to identify patients who can be started on combination therapy upfront. Copyright © 2020 Korean Society for Sexual Medicine and Andrology. [B]KEYWORDS:[/B] Anastrozole; Clomiphene; Hypogonadism; Infertility, male; Testosterone [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Clomid for PCT, fertility or low T
Failed PCT - Getting Off TRT for Fertility Purposes
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top